Evaluation of therapeutics' drug monitoring during cancer chemotherapy: A review

Abstract

Therapeutics' drug monitoring (TDM) has been employed in the clinical patient therapy since early 1960s. In order to minimize toxicity, maximize therapeutic results, or to achieve both, it requires measuring and interpreting drug concentrations in biological fluids and modifying medication dosages or schedules. According to the hypothesis, a drug must meet numerous requirements in order to be useful for TDM. Although, the number of cancer chemotherapy treatment options has grown significantly in recent years. It has been seen that this sector is historically dependent on an outdated method of individual medication dosing based on body size measures (mg/m²) or weight (kg) and still does so in the current healthcare context. TDM is a broad term that applies to a variety of medications from various therapeutic classes, including cardio-active substances, anti-epileptic drugs, anti-inflammatory drugs, respiratory drugs, smooth muscle relaxants, antibiotics as well as few chemotherapy drugs for cancer, immunosuppressants, antidepressants. Despite high inter-individual variability of many anticancer medications, TDM is uncommon in chemotherapy management. In this review, pharmacokinetics is also mentioned in relation to anticancer chemotherapeutic medicines. In this review, the limited instances where oncotherapy practice is currently using TDM are also mentioned and suggested additional pharmaceuticals for which this practice may be appropriate.

Keywords

Oncotherapy / Therapeutics' drug monitoring / Chemotherapy optimization

References

[1] Veal GJ, Coulthard SA, Boddy AV. Chemotherapy individualization. Invest N Drugs. 2003; 21 (2): 149- 156.

[2] Rodman JH, Evans WE. Targeted systemic exposure for pediatric cancer therapy. In: D'Argenio D, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. 1991. New York: Plenum Press; 1991:177-183.

[3] Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem. 1998; 44 (2): 388- 400.

[4] Snozek CLH, McMillin GA, Moyer TP. Therapeutic drugs and their management. In: Burtis CA, Ashwood ER, Philadelphia Bruns D, eds. Tietz Textbook of Clinical Chemistry. 5th ed. WB Saunders Company; 2012:1057-1108.

[5] Masson E, Zamboni WC. Pharmacokinetic optimization of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet. 1997;32(4):324-343.

[6] Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J. Clin.Oncolology. 1990;8:1739-1753.

[7] Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005; 5 (6): 447- 458.

[8] Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003; 4 (4): 224- 232.

[9] Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability. Clin Pharmacokinet. 1998; 34 (4): 323- 333.

[10] Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet. 1986; 11 (3): 223- 235.

[11] Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging. 2002; 19 (1): 25- 42.

[12] Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant. 2000; 14 (2): 97- 109.

[13] Newell DR, Pearson ADJ, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a paediatric dosing formula. J Clin Oncol. 1993; 11 (12): 2314- 2323.

[14] Huitema AD, Mathot RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Therapeut. 2000; 67 (6): 621- 630.

[15] Odoul F, Le Guellec C, Lamagnere JP, et al. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. Fund Clin Pharmacol. 1999; 13 (5): 595- 604.

[16] Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995; 87 (8): 573- 580.

[17] Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract. 2007; 13 (4): 207- 221.

[18] Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. A general model for timedissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Therapeut. 1998; 63 (1): 11- 25.

[19] MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Therapeut. 2000;22(Suppl): B101-B121.

[20] Minami H, Sasaki Y, Saijo N, et al. Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Therapeut. 1998; 64 (5): 511- 521.

[21] Gallo JM, Laub PB, Rowinski EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000; 18 (12): 2459- 2467.

[22] Mick R, Gupta E, Vokes VV, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996; 14 (7): 2012- 2019.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).